pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
◐
Sign In
Subscribe
🐶
home
jobs
news
search
ELI LILLY CO · news · pharmadog
← back to ELI LILLY CO
News mentioning ELI LILLY CO
230
stories
Jun 8, 26
ADA ‘26: Lilly’s dominance, Pfizer’s ‘foundational’ drug and Roche’s ‘me-too’ option
biopharma dive
Jun 8, 26
STAT+: Pharmalittle: We’re reading about Lilly and Pfizer obesity drug data, Roche and J&J deals, and more
stat
Jun 8, 26
#ADA26: Novo Nordisk targets 2030 launch for triple-G obesity shot
endpoints
Jun 8, 26
Major readouts from the annual diabetes conference
stat
Jun 7, 26
STAT+: New data may cast doubt on competitiveness of Boehringer’s obesity drug
stat
Jun 6, 26
STAT+: Lilly shares safety, tolerability data on its next-gen obesity drug
stat
Jun 6, 26
STAT+: Detailed data show Pfizer’s monthly obesity drug continues to show potential
stat
Jun 5, 26
Study data convince Lundbeck to push new migraine drug forward
biopharma dive
Jun 4, 26
STAT+: Supreme Court backs generic drugmaker in ‘skinny labeling’ case
stat
Jun 4, 26
STAT+: For pancreatic cancer patients, an exciting drug can feel out of reach
stat
Jun 4, 26
Lilly, Boehringer retrench in Germany on proposed health spending cuts
endpoints
Jun 4, 26
Alnylam, Inceptive ink AI deal potentially worth $2B
biopharma dive
Jun 4, 26
Otsuka showcases kidney drug data; Pfizer cuts an AI deal
biopharma dive
Jun 4, 26
STAT+: Pharmalittle: We’re reading about fewer pharma investments in Germany, growing U.S. layoffs, and more
stat
Jun 3, 26
What it will take for more employer GLP-1 coverage
endpoints
Jun 3, 26
NewLimit’s $435M megaround; Lilly’s busy dealmaking week
biopharma dive
Jun 3, 26
STAT+: Legend Biotech emerged as a rare market winner
stat
Jun 3, 26
STAT+: Pharmalittle: We’re reading about GLP-1 drugs and knees, FDA cell and gene therapy guidance, and more
stat
Jun 3, 26
Lilly strikes Ascidian deal worth up to $1.9B for RNA editing in kidney diseases
endpoints
Jun 3, 26
Lilly, Ascidian link up in RNA exon editing pact
biopharma dive
Jun 2, 26
Lilly gives hospitals deadline to comply with 340B claims data policy
endpoints
Jun 2, 26
Eli Lilly issues data sharing ultimatum to 340B hospitals
biopharma dive
Jun 2, 26
STAT+: Pharmalittle: We’re reading about a Lilly threat to 340B hospitals, Ebola vaccine funding, and more
stat
Jun 2, 26
STAT+: Online care is caught in the crossfire as states crack down on corporate medicine
stat
Jun 1, 26
STAT+: Eli Lilly warns hospitals to submit claims data in the next five days or lose their 340B drug discounts
stat
Jun 1, 26
#ASCO26: Kelonia Therapeutics delivers an impressive in vivo CAR-T update
endpoints
Jun 1, 26
STAT+: A turning point for pancreatic cancer patients
stat
Jun 1, 26
CDC says containing the spread of Ebola is top priority
stat
Jun 1, 26
Lilly licenses GLP-2 asset from Korean biotech Hanmi for $75M upfront
endpoints
Jun 1, 26
STAT+: Medicare still won’t say how much covering obesity drugs will cost
stat
← prev
page 6 of 8
next →
